Savara Inc (SVRA)

May 06, 2026

Savara faces earnings test ahead of crucial FDA decision By Investing.com - Investing.com Canada

May 06, 2026

May 06, 2026

Savara faces earnings test ahead of crucial FDA decision - Investing.com

May 06, 2026

May 05, 2026

Savara (SVRA) to Release Earnings on Tuesday - MarketBeat

May 05, 2026

May 05, 2026

MSN Money - MSN

May 05, 2026

Apr 30, 2026

SVRA stock slips post-market after FDA delays decision on pulmonary therapy - MSN

Apr 30, 2026

Apr 29, 2026

Savara Grants Equity Awards to 24 New Employees - MyChesCo

Apr 29, 2026

Apr 28, 2026

US High Growth Tech Stocks To Watch - Sahm

Apr 28, 2026

Apr 27, 2026

Savara Inc. ticks higher amid takeover speculation - MSN

Apr 27, 2026

Apr 27, 2026

FDA Extends Review of Savara’s Molgramostim Application to November - MyChesCo

Apr 27, 2026

Apr 26, 2026

Savara to Present Molgramostim Data at ATS 2026 Conference - MyChesCo

Apr 26, 2026

Apr 26, 2026

Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim - Yahoo Finance

Apr 26, 2026

Apr 25, 2026

Savara’s FDA Review Extension Keeps Molgramostim Thesis Intact But Delayed - Sahm

Apr 25, 2026

Apr 24, 2026

Savara Inc ($SVRA) CEO 2025 Pay Revealed - Quiver Quantitative

Apr 24, 2026

Apr 24, 2026

[ARS] Savara Inc SEC Filing - Stock Titan

Apr 24, 2026

Apr 24, 2026

Savara (NASDAQ: SVRA) seeks big share boost and equity plan expansion - Stock Titan

Apr 24, 2026

Apr 24, 2026

Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at Oppenheimer - MarketBeat

Apr 24, 2026

Apr 22, 2026

Savara (SVRA) Stock: Pricing Efficiency Review | Q4 2025: EPS Misses EstimatesLow Growth - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Apr 22, 2026

SVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Apr 22, 2026

Apr 21, 2026

Savara Inc. (NASDAQ:SVRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Apr 21, 2026

Apr 20, 2026

Savara (SVRA) Stock: Why It Could Double (Mini Selloff) 2026-04-20Profit Potential - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 20, 2026

Savara reports 2025 results, advances MOLBREEVI toward approval - MSN

Apr 20, 2026

Apr 20, 2026

Savara Announces New Employment Inducement GrantApril 17, 2026 - BioSpace

Apr 20, 2026

Apr 20, 2026

FY2026 EPS Estimates for Savara Decreased by Lifesci Capital - MarketBeat

Apr 20, 2026

Apr 20, 2026

Savara Inc stock (US80633A1025): Why does its rare disease focus matter more now for investors? - AD HOC NEWS

Apr 20, 2026

Apr 19, 2026

Savara Says UK Regulator Accepts MOLBREEVI Application - MyChesCo

Apr 19, 2026

Apr 18, 2026

Savara (NASDAQ:SVRA) Strengthens Market Presence In Nasdaq Today Biotech Segment - Kalkine Media

Apr 18, 2026

Apr 18, 2026

H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛

Apr 18, 2026

Apr 18, 2026

Savara (NASDAQ:SVRA) Stock Price Up 2.5%Here's Why - MarketBeat

Apr 18, 2026

Apr 17, 2026

How Investors Are Reacting To Savara (SVRA) FDA Priority Review Extension For Molgramostim In Autoimmune PAP - simplywall.st

Apr 17, 2026

Apr 17, 2026

FDA extends review of Savara’s molgramostim application By Investing.com - Investing.com India

Apr 17, 2026

Apr 16, 2026

Savara (SVRA) Receives FDA Review Extension for Molgramostim App - GuruFocus

Apr 16, 2026

Apr 16, 2026

Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16 - 富途牛牛

Apr 16, 2026

Apr 16, 2026

LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Cuts Target Price to $9 - Moomoo

Apr 16, 2026

Apr 16, 2026

Savara gets FDA review extension for lead asset - MSN

Apr 16, 2026

Apr 16, 2026

Savara gets FDA review extension for lead asset (SVRA:NASDAQ) - Seeking Alpha

Apr 16, 2026